Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit...

Area of Science:

• Oncology
• Metabolic pathways
• Cancer research

Background:

• Metabolic reprogramming is a key hallmark of cancer, driving tumor progression.
• Understanding metabolic changes during cancer initiation is crucial for developing prevention strategies.

Purpose of the Study:

• Investigate metabolic alterations during acinar-to-ductal metaplasia (ADM), the initial step in pancreatic carcinogenesis.
• Identify metabolic vulnerabilities in early-stage pancreatic cancer.

Main Methods:

• Analyzed human tissue samples and three mouse models of pancreatic cancer.
• Utilized Seahorse measurements, NMR metabolomics, mass spectrometry, isotope tracing, and RNA sequencing.
• Assessed the impact of blocking metabolic shifts and glutathione synthesis on ADM formation.

Main Results:

• Elevated glycolytic markers observed in human ADM lesions.
• Demonstrated a metabolic switch from oxidative phosphorylation to glycolysis in mouse models of ADM.
• Showed that mitochondrial metabolism is essential for serine and glutathione (GSH) synthesis, but not ATP production.
• MYC mediated increased GSH intermediates, and its inhibition suppressed ADM.

Conclusions:

• Metabolic reprogramming from oxidative phosphorylation to glycolysis is critical for pancreatic cancer initiation.
• MYC-driven glutathione synthesis is a key vulnerability in early pancreatic carcinogenesis.
• Targeting metabolic pathways and GSH synthesis presents potential therapeutic avenues for pancreatic cancer.